A Phase 1/2 Trial of the MEK Inhibitor Selumetinib and Bromodomain Inhibitor AZD5153 with Durvalumab (MEDI4736), a PD-L1 Antibody for Sarcomas Including Malignant Peripheral Nerve Sheath Tumors

PROTOCOL CHAIRS

• AeRang Kim, MD, PhD, Chair
• Brigitte Widemann, MD, Co-Chair